Implementing the optimized hippo‐avoidance prophylactic cranial irradiation for limited‐stage small cell lung cancer by tomotherapy and volumetric modulated arc therapy
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Tian-You Zhan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Radiotherapy, Intensity-Modulated, Cranial Irradiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
Hippo‐avoidance prophylactic cranial irradiation (HA‐PCI) requires a hippocampal avoidance zone expanded from hippocampus to ensure dose fall‐off and compensate for setup errors. Most studies recommend a 5‐mm margin, while it could be optimized to a 2‐mm expansion. Here, we showed the details of optimized HA‐PCI for limited‐stage small cell lung cancer (LS‐SCLC).
Methods
This cohort study reviewed patients with LS‐SCLC receiving optimized HA‐PCI from August 2014 to June 2020 in the National Cancer Center of China. The hippo‐related dose parameters were summarized. The comparison of the Hopkins Verbal Learning Test—Revised (HVLT‐R) scores in different time points was conducted. The Kaplan–Meier method was used to calculate the survival rates.
Results
A total of 112 patients were included. The average doses of hippocampus and hippocampal avoidance zone were 6.80 Gy (IQR: 6.40–7.44) and 7.63 Gy (IQR: 7.14–8.39). No differences were observed in the two radiation techniques (tomotherapy [TOMO] vs. volumetric‐modulated arc therapy [VMAT]). The decline of HVLT‐R score remained in a low level and not significant in assessable patients ( p = 0.095). With a median follow‐up of 52 months (95% CI: 47.2–56.7), the 2‐year overall survival and progression‐free survival were 74.1% and 50.0%, respectively. Two intracranial recurrence lesions (2.3%) located
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
ORCID-Profile: Tian-You Zhan, Tao Zhang, Zong-Mei Zhou
Förderung
- National Key Research and Development Program of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Zhan, T. Y., Deng, L., Wang, W. Q., Zhang, T., Wang, J. Y., Wang, X., Liu, W. Y., Zhai, Y. R., Xiao, Z. F., Feng, Q. F., Bi, N., Li, Y. X., & Zhou, Z. M. (2024). Implementing the optimized hippo‐avoidance prophylactic cranial irradiation for limited‐stage small cell lung cancer by tomotherapy and volumetric modulated arc therapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15462
Vancouver
Zhan TY, Deng L, Wang WQ, Zhang T, Wang JY, Wang X, et al. Implementing the optimized hippo‐avoidance prophylactic cranial irradiation for limited‐stage small cell lung cancer by tomotherapy and volumetric modulated arc therapy. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15462
BibTeX
@article{Zhan2024,
author = {Zhan, Tian-You and Deng, Lei and Wang, Wen-Qing and Zhang, Tao and Wang, Jian-Yang and Wang, Xin and Liu, Wen-Yang and Zhai, Yi-Rui and Xiao, Ze-Fen and Feng, Qin-Fu and Bi, Nan and Li, Ye-Xiong and Zhou, Zong-Mei},
title = {Implementing the optimized hippo‐avoidance prophylactic cranial irradiation for limited‐stage small cell lung cancer by tomotherapy and volumetric modulated arc therapy},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15462}
}
EUVIMED